IDEAYA Biosciences, Inc. — Director's Dealing 2021

Sep 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEAYA Biosciences, Inc. (IDYA)
CIK: 0001676725
Period of Report: 2021-09-07

Reporting Person: Dillon Michael P. (SVP, Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-07	Common Stock	M	116	$4.31	Acquired	78905	Direct
2021-09-07	Common Stock	S	116	$27.4569	Disposed	78789	Direct
2021-09-08	Common Stock	M	7071	$4.31	Acquired	85860	Direct
2021-09-08	Common Stock	M	4313	$11.08	Acquired	90173	Direct
2021-09-08	Common Stock	S	11184	$27.4105	Disposed	78989	Direct
2021-09-08	Common Stock	S	200	$27.67	Disposed	78789	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-07	Stock Option (Right to Buy)	$4.31	M	116	Disposed	2028-02-26	Common Stock (116)	Direct
2021-09-08	Stock Option (Right to Buy)	$4.31	M	7071	Disposed	2028-02-26	Common Stock (7071)	Direct
2021-09-08	Stock Option (Right to Buy)	$11.08	M	4313	Disposed	2029-03-13	Common Stock (4313)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

F5: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.